The insider sales are modest in proportion to market cap and typical of post-vesting diversification. No immediate bearish signal is warranted. Monitor the next 8-K or earnings release for any material developments that may have prompted the CEO's larger-than-usual sale.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jul 17 $39.73entry
- T+1 · 4mo ago −3.42%α −3.26% · $38.37
- T+5 · 4mo ago −5.34%α −4.65% · $37.61
- T+20 · 3mo ago +14.07%α +9.62% · $45.32
- T+60 · due 5w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CareDx (CDNA) CEO John Hanna and Director Hannah Valantine sold a combined ~$5.5M in open-market shares on July 16, 2026, following option exercises. The total sales represent 0.26% of the $2.1B market cap, a modest amount that is not unusual for post-vesting diversification. Insider sales are weak predictors of future returns, and the dollar value relative to company size does not signal material deterioration.
Key Financial Metrics
Key Facts
- CEO John Hanna sold 118,000 shares open-market for ~$4.46M at $36.11–$39.01 per share.
- Director Hannah Valantine sold 28,779 shares open-market for ~$1.04M at $36.14–$36.55.
- Total insider sales of ~$5.5M equal 0.26% of the $2.1B market cap.
- Both insiders exercised options immediately before selling, consistent with routine tax/vesting-related transactions.
- No 10b5-1 plan or other context indicates the sales were pre-planned or reactive to a specific event.
Financial Impact
Insider sales of ~$5.5M, or 0.26% of market cap, represent modest insider unloading.
Risk Factors
- CEO selling a meaningful portion of his holdings (118K shares) could indicate personal diversification or a lack of conviction, but the amount is not alarming.
- If additional insider sales emerge in the next 30 days, the cluster would become more concerning.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CDNA-1784354538852 |
Track record
16 reports on CDNA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.28% at T+60 after the Apr 16, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $77.88 Now $73.72 −5.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $77.88 Now $73.72 −5.34% settles Feb 11
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $81.17 Now $73.72 −9.18% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $80.77 Now $73.72 −8.73% settles Feb 8
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $78.56 Now $73.72 −6.16% settles Feb 4
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $87.41 Now $73.72 −15.66% settles Jan 28
- Oct 29, 202618d ago Institutional Cluster Bearish 4/10 Entry $71.52 Now $73.72 −3.08% settles Jan 27
- Aug 6, 202614w ago Insider Cluster Neutral 3/10 Entry $46.69 to $86.54 Now $73.72 +57.89% ▲ +85.34% +87.47% vs SPY
- Aug 4, 202614w ago 144 Neutral 2/10 Entry $45.50 Now $73.72 +62.02% No price data
- Jul 17, 202617w ago Insider Cluster Neutral 4/10 Viewing Entry $39.73 Now $73.72 +85.55% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers